Action to better inform prescribers and protect patients as part of Agency’s Opioids Action Plan
Silver Spring, Maryland–(ENEWSPF)–August 31, 2016. After an extensive review of the latest scientific evidence, the U.S. Food and Drug Administration announced today that it is requiring class-wide changes to drug labeling, including patient information, to help inform health care providers and patients of the serious risks associated with the combined use of certain opioid medications and a class of central…
